Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Characteristics of cohorts, women with breast cancer stage I–III and IV, diagnosed 2006–2012

From: No association between low-dose aspirin use and breast cancer outcomes overall: a Swedish population-based study

  Stage I–III Stage IV
(n = 21,414) (n = 621)
Age at diagnosis
 < 40 years 883 (4.1) 17 (2.8)
 40–49 years 3114 (14.5) 63 (10.1)
 50–59 years 4597 (21.5) 109 (17.6)
 60–69 years 6546 (30.6) 132 (21.3)
 70–79 years 3679 (17.2) 154 (24.8)
 ≥ 90 years 2595 (12.1) 146 (23.6)
Age (years), median (range) 63 (19–102) 68 (29–97)
Region
 Stockholm-Gotland 9068 (42.4) 235 (37.8)
 Uppsala-Örebro 8868 (41.4) 263 (42.4)
 North 3478 (16.2) 123 (19.8)
Education
 < 10 years 5367 (25.1) 227 (36.6)
 10–12 years 8682 (40.5) 230 (37.0)
 > 12 years 7119 (33.2) 147 (23.7)
 Missing 246 (1.2) 17 (2.7)
Stage
 I 12,546 (58.6) na
 II 7879 (36.8) na
 III 989 (4.6) na
 IV na 621
HER2 status
 Positive 2407 (11.2) 50 (8.1)
 Negative 15,848 (74.0) 147 (23.7)
 Missing 3159 (14.8) 424 (68.3)
ER status
 Positive 17,514 (81.8) 166 (26.7)
 Negative 2907 (13.6) 60 (9.7)
 Missing 993 (4.6) 395 (63.6)
Breast cancer subtype
 Luminal (ER+, HER2/HER2+) 15,529 (72.5) 141 (22.7)
 Nonluminal HER2 (ER, HER2+) 857 (4.0) 34 (5.5)
 ERHER2 1739 (8.1) 18 (2.9)
 Missing 3289 (15.4) 428 (68.9)
Neoadjuvanta/adjuvant breast cancer treatment
 Chemotherapy 8401 (39.2) 97 (15.6)
 Endocrine therapy 16,160 (75.5) 141 (22.7)
 Radiotherapy 15,036 (70.2) 82 (13.2)
 Trastuzumab 1858 (8.7) 21 (3.4)
Aspirin
 Before breast cancer diagnosis (from 9 to 3 months) 2660 (12.4) 100 (16.1)
 After breast cancer diagnosis (3–9 months) 2813 (13.1) na
 During entire follow up 4091 (19.1) na
Aspirin treatment, duration (total, at end of follow-up)
 < 6 months 485 (2.3) na
 6 months–2 years 1552 (7.2) na
 > 2 years 2054 (9.6) na
Dose of aspirin (total, at end of follow-up)
 < 75 mg/day 24 (0.1) na
 75 mg/day 3486 (16.3) na
 > 75 to < 160 mg/day 258 (1.2) na
 160 mg/day 223 (1.0) na
 > 160 mg/day 100 (0.5) na
  1. Data presented as n (%) unless indicated otherwise. ER estrogen receptor, HER2 human epidermal growth factor receptor 2, na not applicable
  2. aNeoadjuvant radiotherapy, 41 women (0.2%); neoadjuvant chemotherapy, 891 women (4.1%); neoadjuvant endocrine therapy, 691 women (3.2%)